Recent studies demonstrate major advances in diagnostics aided by AI and molecular markers. Predicta Biosciences secured $23.4 million in Series A funding to expand its blood cancer and autoimmune disease diagnostics platform employing whole-genome sequencing and immune profiling. Scientists also developed an AI model decoding prostate cancer Gleason scores via MRI and a high-resolution imaging technique (ASA-PD) to visualize pathogenic protein clusters in Parkinson’s disease brains for the first time. These innovations enable earlier detection, personalized treatment, and improved understanding of disease progression.